临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD...临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD)为规范化预测模型的报告过程及报告质量评价提供了指导。本文将采用例解的形式对TRIPOD报告规范各条目进行详细解读,便于临床预测模型领域的研究者更好地掌握及应用该报告规范,进而提高预测模型的报告质量。展开更多
临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD...临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD)为规范化预测模型的报告过程及报告质量评价提供了指导。本文将采用例解的形式对TRIPOD报告规范各条目进行详细解读,便于临床预测模型领域的研究者更好地掌握及应用该报告规范,进而提高预测模型的报告质量。展开更多
BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with ...BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as“GO ASIA”)workgroup.All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017;developed by researchers at the United Kingdom National Health Service;https://qrisk.org/2017/;10-year cardiovascular risk estimation)were included and compared to healthy controls with the same age,sex,and ethnicity.Relative risk was reported.QRISK2 score>10%was defined as the high-CVD-risk group.Fibrosis stages 3 and 4(F3 and F4)were considered advanced fibrosis.RESULTS A total of 1122 patients(73%)had complete data and were included in the final analysis;314(28%)had advanced fibrosis.The median age(interquartile range[IQR])of the study population was 53(44-60)years,532(47.4%)were females,and 492(43.9%)were of Chinese ethnicity.The median 10-year CVD risk(IQR)was 5.9%(2.6-10.9),and the median relative risk of CVD over 10 years(IQR)was 1.65(1.13-2.2)compared to healthy individuals with the same age,sex,and ethnicity.The high-CVD-risk group was significantly older than the low-risk group(median[IQR]:63[59-67]vs 49[41-55]years;P<0.001).Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P<0.001).Median GGT level was not different between the two groups(GGT[U/L]:Median[IQR],high risk 60[37-113]vs low risk 66[38-103],P=0.56).There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r=0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals.Baseline GGT level cannot predict CVD risk in NAFLD patients.However,advanced fibrosis is a predictor of a high CVD risk.展开更多
文摘临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD)为规范化预测模型的报告过程及报告质量评价提供了指导。本文将采用例解的形式对TRIPOD报告规范各条目进行详细解读,便于临床预测模型领域的研究者更好地掌握及应用该报告规范,进而提高预测模型的报告质量。
文摘临床预测模型开发和验证过程的完整报告对于模型外部验证及临床应用至关重要。《个体预后或诊断的多变量预测模型透明报告》(Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis,TRIPOD)为规范化预测模型的报告过程及报告质量评价提供了指导。本文将采用例解的形式对TRIPOD报告规范各条目进行详细解读,便于临床预测模型领域的研究者更好地掌握及应用该报告规范,进而提高预测模型的报告质量。
文摘BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as“GO ASIA”)workgroup.All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017;developed by researchers at the United Kingdom National Health Service;https://qrisk.org/2017/;10-year cardiovascular risk estimation)were included and compared to healthy controls with the same age,sex,and ethnicity.Relative risk was reported.QRISK2 score>10%was defined as the high-CVD-risk group.Fibrosis stages 3 and 4(F3 and F4)were considered advanced fibrosis.RESULTS A total of 1122 patients(73%)had complete data and were included in the final analysis;314(28%)had advanced fibrosis.The median age(interquartile range[IQR])of the study population was 53(44-60)years,532(47.4%)were females,and 492(43.9%)were of Chinese ethnicity.The median 10-year CVD risk(IQR)was 5.9%(2.6-10.9),and the median relative risk of CVD over 10 years(IQR)was 1.65(1.13-2.2)compared to healthy individuals with the same age,sex,and ethnicity.The high-CVD-risk group was significantly older than the low-risk group(median[IQR]:63[59-67]vs 49[41-55]years;P<0.001).Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P<0.001).Median GGT level was not different between the two groups(GGT[U/L]:Median[IQR],high risk 60[37-113]vs low risk 66[38-103],P=0.56).There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r=0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals.Baseline GGT level cannot predict CVD risk in NAFLD patients.However,advanced fibrosis is a predictor of a high CVD risk.
